Audio

Community Oncology Podcast: T-DM1 in HER-2 positive breast cancer

Publish date: March 31, 2013

 

Editor-in-Chief Dr. David Henry highlights articles on T-DM1 for advanced HER2-positive breast cancer and an original research report from US Oncology on treatment patterns in women with HER2-/HR-positive breast cancer. He also looks at two case letters, one on plasmablastic lymphoma in the ileum, and a second on methotrexate-induced erythema multiforme, as well as a column by an oncology fellow on being a first-year fellow and first-year mom.

Recommended Reading

Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32
MDedge Hematology and Oncology
A randomized, double-blind, placebo-controlled study of oral coenzyme Q 10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer
MDedge Hematology and Oncology
Metastatic breast cancer incidence is rising among young women
MDedge Hematology and Oncology
Direct access to unexpected genetic test results
MDedge Hematology and Oncology
Imaging agent approved for locating lymph nodes
MDedge Hematology and Oncology
Lipid metabolism genes linked to breast cancer subtype
MDedge Hematology and Oncology
Breast cancer: Cardiac risk increases with radiation dose to heart
MDedge Hematology and Oncology
Contralateral prophylactic mastectomy adds complications
MDedge Hematology and Oncology
Trastuzumab emtansine in advanced HER2-positive breast cancer
MDedge Hematology and Oncology
Treatment patterns in HER2-/HR-positive postmenopausal women with metastatic breast cancer initiating first-line treatment in a community oncology setting in the US
MDedge Hematology and Oncology